New York, June 4, 2026, 06:01 (EDT)
- Veeva shares traded at $178.72, off roughly 2.5% ahead of the New York market open.
- Veeva said fiscal Q1 revenue gained 16% to $882.9 million. Subscription revenue was up 15% to $730.2 million.
- Veeva now sees fiscal 2027 revenue at $3.635 billion to $3.645 billion and roughly $9.05 in adjusted EPS.
Veeva Systems stock was lower before the open on Thursday. The life-sciences software group topped quarterly estimates and raised its forecast for the full year, but investors still had questions about AI, services growth, and customer shifts, even after what looked like a solid report.
Veeva shares were quoted at $178.72, down $4.54, or about 2.5%, in premarket trading in New York. The drop followed Veeva’s fiscal first-quarter revenue of $882.9 million, beating the consensus estimate of $857.75 million from Investing.com. Adjusted EPS was $2.24, also above the $2.14 estimate.
Timing is key here. Software investors are showing less patience for big AI plans that don’t spell out how they’ll bring in revenue. Veeva is out to prove its long track record in drug-industry software gives it an edge as it moves into AI agents — software meant to handle actual work tasks for clients, instead of just replying to questions.
Veeva reported a 16% jump in total revenue for the quarter ended April 30, with subscription revenue up 15% from a year earlier. Non-GAAP operating income reached $395.4 million, up from $349.9 million. The figure leaves out items such as stock-based compensation.
Veeva CFO Brian Van Wagener said the quarter beat all guidance and saw broad growth and profit. The company now sees second-quarter revenue at $902 million to $905 million and raised its fiscal 2027 revenue forecast to a range of $3.635 billion to $3.645 billion.
Veeva CEO Peter Gassner talked up AI, saying its current progress “sets the foundation” for what’s next. The company wants to be seen as more than a software vendor and is now selling itself as a provider of apps and AI agents to the life-sciences sector. Veeva Investor Relations
Veeva reported it signed up 27 new Vault CRM customers last quarter, putting its total users above 150. CRM software lets companies run sales, marketing and medical talks with groups like doctors and health systems.
AI launches keep picking up. Veeva said over 50 brands now use Ostro, the conversational AI firm it acquired in March. Vault AI is set to roll out for all Vault apps in August. Early adopters will get access to Veeva Falcon before the end of the year.
Veeva Development Cloud’s SVP Rik van Mol called Vault AI and Falcon “a significant step in AI-enabling life sciences.” Veeva said Falcon will start by handling trial master file document intake, doing quality checks, working on regulatory correspondence with health authorities, and helping with safety case triage. PR Newswire
Veeva makes it clear the competition is direct. The company’s most recent annual filing points to Salesforce as the main rival in CRM products. IQVIA is in the mix too, with a CRM license deal with Salesforce. Veeva flagged a risk in its shift to Vault CRM, saying some customers have picked or could pick other vendors.
Raymond James dropped its price target on the stock to $225 from $275 but stuck with an Outperform call. The bank said the beat-and-raise headline was strong, though it pointed out that some investors might look past the guidance hike due to services and deals. It also mentioned that swings in the software sector could hit the shares.
But the downside risk is clear. If AI revenue is slow to show up, or if Vault CRM conversions lag as Salesforce pushes more into life sciences, the market could keep seeing Veeva’s AI push as more story than earnings. Veeva’s own filing lists risks like tougher rivals, pricing pressure or losing customers that could cut into revenue and margins.
Thursday’s main trading session is next for Veeva. Premarket trading was down. The company posted a beat and lifted its outlook, but shares didn’t recover. Investors are used to Veeva delivering beats and higher forecasts. Market response this time suggests there’s still caution—Wall Street wants more definite signs that Veeva’s AI and CRM moves will stick and drive recurring revenue.
